Global GLP-1 Drug Market Strategic Research Report 2026-2031

The global GLP-1 drug market is undergoing one of the most consequential competitive reversals in recent pharmaceutical history. As per this report, the global GLP-1 drug market which was worth USD 70.58 billion in 2025 is expected to grow at a CAGR of 12.8% between 2026 and 2031, reaching approximately USD 145.39 billion by 2031, driven by dual-indication demand across type 2 diabetes and obesity/weight management.

This report's single most consequential finding is a real, ongoing competitive leadership reversal: Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) overtook Novo Nordisk's semaglutide franchise (Ozempic/Wegovy) for US GLP-1 market leadership during 2025, reaching an estimated 57% US market share -- a position Novo Nordisk had held since the category's commercial inception. Tirzepatide's dual-mechanism action as both a GIP and GLP-1 receptor agonist has demonstrated clinically superior weight reduction outcomes versus semaglutide in head-to-head trial data.

The financial consequences are historic: Eli Lilly's market capitalisation crossed USD 1 trillion in August 2026, making Lilly the first healthcare company in history to reach that valuation threshold. Tirzepatide was confirmed as the world's best-selling drug by revenue in the third quarter of 2025, a milestone reached in under three years of commercial availability.

This report profiles eight key competitors including Eli Lilly, Novo Nordisk, Biocon Biologics, Amgen, Viking Therapeutics, Zealand Pharma, Hanmi Pharmaceutical, and Roche/Genentech, with detailed indication-level, regional, and competitive analysis through 2031.

Scope of Global GLP-1 Drug Market Strategic Research Report 2026-2031

• This report provides forecast data by value (USD Billion) for the global GLP-1 drug market, with 2025 as the base year and forecasting to 2031.
• This report provides segmentation by indication (Type 2 Diabetes, Obesity/Weight Management) and by delivery format.
• This report provides region-wise forecast data by value.
• This report identifies key growth drivers and inhibitors affecting the global GLP-1 drug market.
• This report provides company profiles including Company Overview, Key Products, Financial Performance, Business Strategy, and SWOT Analysis for key companies.
• This report provides Porter's Five Forces, PESTLE, and SWOT analysis for the global GLP-1 drug market.
• This report identifies key future trends including oral formulation development and biosimilar entry.

Who can use the Global GLP-1 Drug Market Research Report?

This research report is ideal for people who wish to gain a thorough understanding of the GLP-1 drug market. Some of the intended users for this report are:

• C-level executives and Company Directors in pharmaceutical companies
• Commercial strategy and market access professionals
• Industry consultants and Management consultants
• Investment managers, Financial professionals, and Venture Capitalists
• Bank Managers, M&A Managers, and Auditors
• Anyone operating in the GLP-1 drug value chain.